EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical Implementation of Pharmacogenomics and Drug–Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow‐Up

Roman Tremmel iD, Filippa Schreeck iD, Simon Jaeger iD, Severin Schricker iD, Elke Schaeffeler iD, Svitlana Igel iD, Daniela Steinberger iD, Manuel Pagitz, Jörg Latus iD, Markus Ketteler iD, Kerstin Bühl, Marc-H Dahlke iD und 2 weitere

Clinical Pharmacology & Therapeutics · 2026-01 · 119 (1) · 241-254

DOI: 10.1002/cpt.70083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 11.10.2025. Verfasst von Roman Tremmel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany. Hauptthemen laut MEDLINE: Hospitals, Teaching, Pharmacogenetics, Pharmacogenomic Testing. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacogenomics (PGx) helps to explain variability in drug response, including adverse drug reactions. Functional variants in genes affecting drug absorption, distribution, metabolism, and excretion (ADME) have been described. Despite PGx guidelines (e.g., CPIC and DPWG) enabling genotype‐guided drug and dose selection, preemptive implementation remains challenging due to various issues including standardized result communication and integration into electronic health record (EHR) systems. We implemented PGx testing as well as drug–drug interaction (DDI) screening in a German academic hospital and assessed their impact on physicians, general practitioners (GPs), and patients. A novel PGx workflow was established using a 60‐genetic variant panel. CPIC/DPWG guideline‐based PGx reports were integrated into the EHR system and provided as a mobile and web application for patients through a genetic information system. Medication profiles and questionnaires evaluated PGx‐based decisions 3 months post‐discharge. Among 255 patients, 95% had at least one actionable PGx variant, most commonly affecting statins, 5‐fluorouracil, irinotecan, and pantoprazole. Actionable recommendations were provided in 21.5%, with hospital physicians modifying treatment subsequently in 75.5%. We identified 57 clinically significant DDIs, including PGx drugs in 21%. GPs maintained optimized treatment in 77% of those patients with a medication change initiated during hospitalization. One in 10 patients discussed results with their GPs. GPs favored PGx for future prescriptions and requested training. We showed that preemptive PGx testing can be successfully implemented in a German hospital with high acceptance among physicians and GPs, and that PGx integration into the EHR supports broader adoption in precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hospitals, TeachingPharmacogeneticsPharmacogenomic TestingHumansDrug InteractionsGermanyMaleFemaleMiddle AgedAgedElectronic Health RecordsAdultFollow-Up StudiesDrug-Related Side Effects and Adverse ReactionsAcademic Medical CentersPrecision Medicine

Autor:innen und Institutionen

  • Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
  • University of Tuebingen, Tuebingen, Germany.
  • Institute of Clinical Pharmacology, Paracelsus Medical University, Nuremberg, Germany.
  • Department of General Internal Medicine and Nephrology, Robert Bosch Hospital, Stuttgart, Germany.
  • bio.logis digital health GmbH, Frankfurt am Main, Germany.
  • Institute of Humangenetics, Justus Liebig University, Giessen, Germany.

ORCID-Profile: Roman Tremmel, Filippa Schreeck, Simon Jaeger, Severin Schricker, Elke Schaeffeler, Svitlana Igel, Daniela Steinberger, Jörg Latus, Markus Ketteler, Marc-H Dahlke, Hans-Georg Kopp, Matthias Schwab

Zitieren

APA

Tremmel, R., Schreeck, F., Jaeger, S., Schricker, S., Schaeffeler, E., Igel, S., Steinberger, D., Pagitz, M., Latus, J., Ketteler, M., Bühl, K., Dahlke, M. H., Kopp, H. G., & Schwab, M. (2026). Clinical Implementation of Pharmacogenomics and Drug–Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow‐Up. Clinical Pharmacology & Therapeutics, 119(1), 241-254. https://doi.org/10.1002/cpt.70083

Vancouver

Tremmel R, Schreeck F, Jaeger S, Schricker S, Schaeffeler E, Igel S, et al. Clinical Implementation of Pharmacogenomics and Drug–Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow‐Up. Clinical Pharmacology & Therapeutics. 2026;119(1):241-254. doi:10.1002/cpt.70083

BibTeX
@article{Tremmel2026,
  author = {Tremmel, Roman and Schreeck, Filippa and Jaeger, Simon and Schricker, Severin and Schaeffeler, Elke and Igel, Svitlana and Steinberger, Daniela and Pagitz, Manuel and Latus, Jörg and Ketteler, Markus and Bühl, Kerstin and Dahlke, Marc-H and Kopp, Hans-Georg and Schwab, Matthias},
  title = {Clinical Implementation of Pharmacogenomics and Drug–Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow‐Up},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {119},
  number = {1},
  pages = {241--254},
  doi = {10.1002/cpt.70083}
}
Kostenlos starten →